Cannabis-based products for medicinal use – NHS England

Following the Government’s announcement to reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians following the re-scheduling which sets out our expectations of what this regulatory change will mean in practice for clinicians working in

Ensuring access to medicines: How to stimulate innovation to meet patients’ needs?: (Policy Brief 29) – European Observatory on Health Systems and Policies

Brief that aims to inform discussions about stimulating more meaningful productivity in terms of pharmaceutical R&D. More specifically, it explores how R&D efforts can be steered to areas of unmet clinical needs and how efficiency in the R&D process can

Interim protocol on dispensing of adrenaline auto-injectors, 150microgram – NHS England

This guidance on the dispensing of adrenaline auto-injectors (150microgram) has been developed for pharmacies and dispensing GP practices. This validation protocol has been developed to ensure consistent practice nationally and to prevent the need for any local re-interpretation.

Antimicrobial resistance: Eleventh Report of Session 2017–19: Report, together with formal minutes relating to the report – House of Commons Health and Social Care Committee

House of Commons Health and Social Care Committee report that identifies that tackling antimicrobial resistance needs to be firmly established as a ‘top five policy priority’ for the government in order to help prevent the virtual loss of worldwide modern

Junior Epipen shortage: letter to parents and guardians from Dr Aidan Fowler, National Director of Patient Safety – NHS England

Experts in children’s allergies have developed the advice in this letter to support parents and guardians of children who use Epipen Junior 150mcg.

Burosumab for treating X-linked hypophosphataemia in children and young people: Highly specialised technologies guidance [HST8] – NICE

Evidence-based recommendations on burosumab (Crysvita) for X‑linked hypophosphataemia in children and young people. Burosumab is recommended, within its marketing authorisation, for treating X‑linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in

Cabozantinib for untreated advanced renal cell carcinoma: Technology appraisal guidance [TA542] – NICE

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults. Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate‑ or poor‑risk as defined in the International Metastatic Renal

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs: Technology appraisal guidance [TA543] – NICE

Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs. It recommends:  Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as

Price increases for generic medications: Sixty-Second Report of Session 2017–19: Report, together with formal minutes relating to the report – House of Commons Committee of Public Accounts

During 2017, the prices of certain generic medicines purchased by community pharmacies for the NHS increased unexpectedly, affecting an unusually high number of medicines. Although the Department of Health & Social Care (the Department) and its arms-length bodies took action

Surveillance of antimicrobial resistance in Neisseria gonorrhoeae in England and Wales: Key findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP): Data to May 2018 – Public Health England

Data on trends in antimicrobial resistance and decreased susceptibility in gonococcal infection in England and Wales provided by GRASP. Public Health England reports annually on drug resistance and decreased susceptibility in gonorrhoea in England and Wales and has twice provided data

Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) – NHS England

Updated policy document outlines the arrangements for funding of the use of cobicistat as a booster in treatment of HIV infection (all ages).

Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer: Interventional procedures guidance [IPG628] – NICE

Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using microwaves to improve the effect of the chemotherapy given directly into the bladder. This guidance replaces NICE interventional procedures guidance on intravesical microwave

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia: Technology appraisal guidance [TA541] – NICE

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia

Pharmacological management of migraine: (SIGN 155) – Scottish Intercollegiate Guidelines Network

This guideline provides recommendations on the pharmacological management of adults with acute migraine, and prophylaxis for patients with episodic or chronic migraine or medication overuse headache. This guideline will be of interest to healthcare professionals in primary and secondary care,

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: Technology appraisal guidance [TA540]

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults. Pembrolizumab is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin. Pembrolizumab

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours: Technology appraisal guidance [TA539] – NICE

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults. Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive